Valuation: Amicus Therapeutics

Market Cap 454.99Cr 413.36Cr 381.92Cr 344.98Cr 651.03Cr 43TCr 673.93Cr 4.59TCr 1.82TCr 23TCr 1.71TCr 1.67TCr 73TCr P/E 2024
-51.1x
P/E 2025 -162x
Enterprise Value 469.87Cr 426.88Cr 394.41Cr 356.26Cr 672.32Cr 44TCr 695.97Cr 4.74TCr 1.88TCr 24TCr 1.76TCr 1.73TCr 75TCr EV / Sales 2024
5.69x
EV / Sales 2025 7.18x
Free-Float
99.31%
Yield 2024 *
-
Yield 2025 -
Change 5-day change 1-year change 3-year change Capi.($)
+1.57%+1.65% - - 454.99Cr
-1.29%-1.76%+51.98%+64.66% 6.63TCr
-0.09%+2.79%+10.75%+95.02% 6.06TCr
+0.63%+1.64%+24.25%+89.70% 5.55TCr
-0.60%-0.53%+10.22%+119.45% 4.76TCr
-0.27%-5.28%+22.20%+28.97% 4.37TCr
-2.44%-16.09%+142.91%+690.35% 3.73TCr
+0.23%+1.66%+14.85%+49.06% 3.66TCr
+2.35%-3.61%+78.64%+60.70% 3.22TCr
+2.67%+6.80%-37.18%+407.36% 2.66TCr
Average +0.29%+0.33%+35.40%+178.36% 5TCr
Weighted average by Cap. -0.04%+0.33%+35.23%+153.27%

Financials

2024 2025
Net sales 53Cr 48Cr 44Cr 40Cr 76Cr 4.96TCr 78Cr 533.29Cr 211.3Cr 2.66TCr 198.24Cr 194.04Cr 8.43TCr 63Cr 58Cr 53Cr 48Cr 91Cr 5.95TCr 94Cr 640.21Cr 253.66Cr 3.2TCr 237.98Cr 232.95Cr 10TCr
Net income -5.61Cr -5.1Cr -4.71Cr -4.25Cr -8.03Cr -526.81Cr -8.31Cr -57Cr -22Cr -282.71Cr -21Cr -21Cr -895.5Cr -2.71Cr -2.46Cr -2.28Cr -2.06Cr -3.88Cr -254.55Cr -4.02Cr -27Cr -11Cr -136.6Cr -10Cr -9.96Cr -432.7Cr
Net Debt 19Cr 18Cr 16Cr 15Cr 28Cr 1.82TCr 29Cr 195.53Cr 77Cr 976.01Cr 73Cr 71Cr 3.09TCr 15Cr 14Cr 12Cr 11Cr 21Cr 1.4TCr 22Cr 150.23Cr 60Cr 749.91Cr 56Cr 55Cr 2.38TCr
Logo Amicus Therapeutics
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Employees
-